Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Acquisitions News
Ophthalmology Sees $6.3 Billion in Total Investment in 2024, With 18 M&A Transactions
The ophthalmic market continues to expand and attract funding from a wide variety of investors. Total amounts raised in 2024 reached over $6.3 billion. Venture capital investment in ophthalmology i...
Bausch Kicks off 2025 With Series of Research Deals, Plus an IOL Launch
Bausch + Lomb has recently announced a series of acquisitions and collaborations that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. It also launched an ...
2024 in Review: Alcon Expands Its Glaucoma Portfolio With Belkin Acquisition
Alcon completed its acquisition of Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, in July 2024. The purchase expands Alcon’s presence in the glaucoma market; Alcon also offers the H...
Bausch + Lomb Acquires Elios Vision, Developer of Excimer Laser Trabeculostomy
Bausch + Lomb announced Dec. 11 that an affiliate had acquired Elios Vision, developer of the Elios excimer laser trabeculostomy procedure for glaucoma. No financial details were disclosed. Elios’ ...
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase
Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....
ANI to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 mil-lion up front. The deal is expected to close in late Q3-2024, the ...
ANI Pharmaceuticals to Acquire Alimera Sciences, Maker of Iluvien and Yutiq, for $381 Million
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335M
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
Science Corporation, of Alameda, California, reported April 25 that it had acquired the IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the d...
Alcon to Acquire Glaucoma Laser Company Belkin Vision for up to $335 Million
Alcon is acquiring Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, for up to $335 million, according to reports. The value of the transaction was first estimated in a story dated May...
California-Based Science Corporation Acquires Pixium Vision’s Prima Implant
Science Corporation, of Alameda, California, reported April 25 that it had acquiredthe IP and related assets for the Prima retinal implant, developed by Pixium Vision SA, of France. Terms of the de...
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition
Carl Zeiss Meditec’s acquisition of DORC (Dutch Ophthalmic Research Center) will change the players in the retinal surgical equipment market, but whether it will lead to any major changes in market...
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.